Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia

Date Published: 22-Aug-22

Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia

• Authors: Qi Zhang, Bridget Riley-Gillis, Lina Han, Yannan Jia, Alessia Lodi, Haijiao Zhang, Saravanan Ganesan, Rongqing Pan, Sergej N. Konoplev, Shannon R. Sweeney, Jeremy A. Ryan, Yulia Jitkova, Kenneth Dunner Jr, Shaun E. Grosskurth, Priyanka Vijay, Sujana Ghosh, Charles Lu, Wencai Ma, Stephen Kurtz, Vivian R. Ruvolo, Helen Ma, Connie C. Weng, Cassandra L. Ramage, Natalia Baran, Ce Shi, Tianyu Cai, Richard Eric Davis, Venkata L. Battula, Yingchang Mi, Jing Wang, Courtney D. DiNardo, Michael Andreeff, Jeffery W. Tyner, Aaron Schimmer, Anthony Letai, Rose Ann Padua, Carlos E. Bueso-Ramos, Stefano Tiziani, Joel Leverson, Relja Popovic & Marina Konopleva
• Journal: Signal Transduction and Targeted Therapy
• DOI: 10.1038/s41392-021-00870-3
• Cited AcceGen Product/Service: KO52